Антибактериальная терапия инфекций нижних дыхательных путей: фокус на моксифлоксацин

1. Naber K, Adam D. Expertengruppe der PEG. Einteilung der Fluorchinolone. Chemother J 1998; 7: 66–8.
2. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (3): 186–226.
3. Kothe H, Bauer T, Marre R et al; Competence Network for Community-Acquired Pneumonia study group. Eur Respir J 2008; 32: 139–46.
4. Fogarty CM, Grossman C, Williams J et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748–63.
5. Peptipretz P, Arvis P, Marel M et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185–95.
6. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 153–43.
7. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous and oral moxifloxacin compared with sequential intravenous and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746–54.
8. Katz E, Larsen IS, Fogarty CM et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004; 27: 395–405.
9. Welte T, Petermann W, Schuermann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697–705.
10. Anzueto A, Niederman MS, Pearle J et al. Community-acquired pneumonia in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81.
11. Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46: 1499–509.
12. Wenisch C, Krause R, Szell M et al. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment. Infection 2006; 34: 190–5.
13. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730–54.
14. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134–41.
15. Lode H, Grossman C, Choudhri S et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003; 97: 1134–42.
16. Hoffken G, Barth J, Rubinstein E et al. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection 2007; 35: 414–20.
17. Нозокомиальная пневмония у взрослых (Национальные рекомендации). Клин. микробиология и антимикроб. химиотерапия. 2009; 11 (2): 100–42.
18. Hammond JM, Potgieter PD, Hamslo D et al. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995; 108: 937–41.
19. Ott SR, Allewelt M, Lorenz J et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 23–30.
20. Polenakovik H, Burdette SD, Polenakovik S. Moxifloxacin is efficacious for treatment of community-acquired lung abscess in adults. Clin Infect Dis 2005; 41: 764–65.
21. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
22. Романовских А.Г., Синопальников А.И. Инфекции нижних дыхательных путей у взрослых: диагностика, антибактериальная терапия, профилактика. (По материалам рекомендаций Европейского респираторного общества и Европейского общества по клинической микробиологии и инфекционным болезням.) Клин. микробиология и антимикроб. химиотерапия. 2006; 8 (3): 206–16.
23. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501–13.
24. DeAbate CA, Mathew CP, Warner JH et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029–37.
25. Kreis SR, Herrera N, Golzar N et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Manage 2000; 7: 33–7.
26. Chodosh S, DeAbate CA, Haverstock D et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000; 94: 18–27.
27. Hautamaki D, Bruya T, Kureishi A et al. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Todays Ther Trends 2001; 19: 117–36.
28. Schaberg T, Ballin I, Huchon G et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29: 314–28.
29. Grassi C, Casali L, Curti E et al. Efficacy and safety of short course (5-day) moxifloxain vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002; 14: 597–608.
30. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–64.
31. Global Strategy for the Diagnosis, Management, and Prevention of COPD. http://www.goldcopd.com
32. Синопальников А.И., Романовских А.Г. Инфекционное обострение хронической обструктивной болезни легких. В кн. А.И.Синопальникова, Р.С.Козлова «Внебольничные инфекции дыхательных путей. Руководство для врачей». М.: Премьер МТ, Наш Город, 2007; с. 267–94.
33. Black P, Staykova T, Chacko E et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; 1: CD004105.
34. Sethi S, Jones PW, Theron MS et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11 (http://respiratory-research.com/content/11/1/10).
35. O’Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J 2008; 15 (Suppl. A): 1A–8A.
36. Personal communication: www.infectweb.com
37. Ball P, Stahlmann R, Kubin R et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940–50.
38. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of safety profile of oral moxofloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28: 443–52.
39. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115–39.
40. Iannini PB, Kubin R, Reiter C. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, USA (2002) (Poster L-374).
41. Owens RC, Ambrose PG. Atnimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144–S157.
42. Avelox® 400 mg film-coated tablets. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc., Leverkusen, Germany, Revised March 2008.
43. Veyssier P, Voirot P, Begaud B et al. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study) [in French]. Med Mal Infect 2006; 36: 505–12.
44. US Avelox® package insert [online]. Available from URL: http://www.univgraph.com/bayer/inserts/avelox.pdf [Accessed 2009 March 18].
45. Johannes CB, Ziyadeh N, Seeger JD et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organization. Drug Saf 2007; 30: 705–13.
46. Dhalla IA, Mamdani MM, Simor AE et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antomicrob Agents Chemother 2006; 50: 3216–9.
47. EMEA. Annex II. The scientific conclusions and the grounds for amendments of the summary of product characteristics and package leaflet. December 2008. http://www.ec.europa.eu/ enterprise/pharmaceutials/register/refh_others.htm
48. Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512–21.
49. Salvo F, Polimeni G, Moretti U et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007; 60: 121–6.
50. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359–78.
51. Страчунский Л.С., Кречиков  В.А. Моксифлоксацин – фторхинолон нового поколения с широким спектром активности. Клин. микробиология и антимикроб. химиотерапия. 2001; 3 (3): 243–58.

А.И.Синопальников
 
Российская медицинская академия последипломного образования, Москва